Search
Vicriviroc
go.drugbank.com/drugs/DB06652InvestigationalVicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of HIV-1. … This pyrimidine based drug inhibits the interaction of HIV-1 with CCR5, preventing viral entry into cells. This drug was developed by Schering-Plough.
Viral Macrophage-Inflammatory Protein
go.drugbank.com/drugs/DB15748ExperimentalThe structure of vMIP consists of 71 residues and is a monomer under most conditions.
Tifuvirtide
go.drugbank.com/drugs/DB05413InvestigationalTifuvirtide is the first members of a new class of anti-HIV drugs which is also called fusion inhibitors. It has received fast-track designation from the FDA and is in Phase I/II clinical testing.
CTCE-0214
go.drugbank.com/drugs/DB05934ExperimentalCTCE-0214 is a stable peptide agonist of stromal cell-derived factor-1 (SDF-1), a key signaling molecule in the proliferation, homing, engraftment and expansion of hematopoietic stem cells and white blood
iCo-007
go.drugbank.com/drugs/DB05268InvestigationaliCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis
L-tartaric acid
go.drugbank.com/drugs/DB09459Approvedorganic acid that occurs naturally in many plants, most notably in grapes.Tartaric is an alpha-hydroxy-carboxylic acid, is diprotic and aldaric in acid characteristics, and is a dihydroxyl derivative of
Mixtures: SAL G.16-Bromoepiandrosterone
go.drugbank.com/drugs/DB05107Investigational16-Bromoepiandrosterone is an injectable formulation of a compound called alpha-epi-bromide. … It is a chemical relative of DHEA which was selected for development after it showed antiretroviral activity in laboratory tests.
Ulotaront
go.drugbank.com/drugs/DB15665InvestigationalAdditional clinical trials of SEP-363856 are required to confirm the safety and efficacy of this drug.[A193506] … SEP-363856 is a novel psychotropic drug being investigated for the treatment of schizophrenia.
VLTS-589
go.drugbank.com/drugs/DB05430InvestigationalVLTS-589 consists of plasmid encoding the angiomatrix protein Del-1 in conjunction with poloxamer 188 for the treatment of peripheral vascular disease.